FDA draft guidance would let one licence cover many gene-editing variants

The Food and Drug Administration has published draft guidance addressing one of the harder regulatory questions raised by gene editing: how to license a therapy that is, in effect, redesigned for each patient. The agency announced the availability of the draft, titled "Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management," in the Federal Register on 28 October 2026, under docket number FDA-2026-D-11783 [s1].

The problem the draft addresses

Individualised genome editing products are therapies in which the editing component is tailored to a specific patient's genetic sequence. That means a single product line can contain many closely related variants, one per patient, rather than one fixed formulation made for everyone. The draft guidance provides recommendations for how such a product, when it includes multiple product variants, can be submitted in a single Biologics License Application under section 351(a) of the Public Health Service Act [s1].

When finalised, the FDA says, the guidance will describe its current thinking on how to specify the extent of genome-editing component variation within a single application, and how to add new product variants to that licence after it has been granted [s1]. In plain terms, the agency is sketching a way for a developer to obtain one licence that anticipates and accommodates future patient-specific versions, instead of filing a fresh application each time a new patient's variant is made.

What else the guidance covers

Beyond the core submission question, the draft addresses a set of related topics that each variant raises: the potency and safety evaluation of product variants, manufacturing process validation, labelling and indication statements, and drug naming and identification [s1]. These are the practical hurdles of a one-licence-many-variants model — how to show each version works and is safe, how to validate a manufacturing process that produces different end products, and how to name and label them.

The FDA frames the document as a complement to guidances it has already issued on genome-editing products. It cites its January 2024 guidance on "Human Gene Therapy Products Incorporating Human Genome Editing," a February 2026 draft on using a "plausible mechanism framework" to develop individualised therapies for genetic conditions with a known biological cause, and a June 2026 draft on leveraging prior knowledge across genome-editing programmes [s1]. The new draft adds advice specifically on preparing and submitting the licence application and its supplements, rather than repeating the earlier material [s1].

A draft, not a rule

Like other FDA guidances, this document is being issued under the agency's good guidance practices regulation at 21 CFR 10.115 [s1]. The agency is explicit about its legal weight: when finalised, the guidance will represent the FDA's current thinking, "does not establish any rights for any person and is not binding on FDA or the public," and developers may use an alternative approach that satisfies the applicable statutes and regulations [s1]. It is intended for sponsors and applicants developing individualised genome-editing products [s1].

The guidance is addressed through the Center for Biologics Evaluation and Research, reflecting that these products are regulated as biologics rather than as conventional small-molecule drugs [s1]. The agency also notes that, as it develops a final version, it will consider comments on the costs or cost savings the guidance may generate, a consideration tied to Executive Order 14192 [s1].

The comment window

The timing is defined. The FDA asks for electronic or written comments on the draft by 27 November 2026 to ensure the agency considers them before it begins work on the final version, though under its regulations comments on any guidance may be submitted at any time [s1]. The draft and its docket are available on the federal rulemaking portal and through the agency's biologics guidance pages [s1].

What is settled and what is not

What is fixed is that a dated draft now exists, a docket is open, and the FDA has stated a direction: individualised genome-editing products with multiple variants may, in the agency's current thinking, be brought forward under a single licence rather than many [s1]. That is a meaningful signal for a field in which each patient's therapy can differ.

What is not settled is the substance. A draft guidance is a proposal; the specific recommendations on variation, post-licensure additions, potency testing and naming can be revised, narrowed or expanded in response to comment before the FDA finalises them [s1]. Until then the document functions as a statement of the agency's direction on patient-specific gene editing — authoritative as current thinking, but neither binding nor final [s1].